Novavax (NVAX) Revenue (2010 - 2026)

Novavax's Revenue history runs 17 years deep, the most recent figure standing at $139.5 million for Q1 2026.

• On a quarterly basis, Revenue fell 79.07% year-over-year to $139.5 million in Q1 2026; TTM through Mar 2026 was $532.1 million, a 57.6% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 64.69% from the prior year.
• Revenue declined to $139.5 million in Q1 2026 per NVAX's latest filing, from $147.1 million in the prior quarter.
• Across five years, Revenue topped out at $734.6 million in Q3 2022 and bottomed at $70.4 million in Q3 2025.
• The 5-year median for Revenue is $185.9 million (2022), against an average of $285.1 million.
• Across the five-year window, Revenue tumbled 88.5% in 2023 and surged 610.3% in 2025, its largest moves.
• Year by year, Revenue stood at $357.4 million in 2022, then fell by 18.48% to $291.3 million in 2023, then plunged by 69.69% to $88.3 million in 2024, then surged by 66.61% to $147.1 million in 2025, then declined by 5.18% to $139.5 million in 2026.
• Per Business Quant, the three latest NVAX Revenue figures stand at $139.5 million (Q1 2026), $147.1 million (Q4 2025), and $70.4 million (Q3 2025).